GDOC Goldman Sachs Future Health Care Equity ETF
ETF on NYSE (US) · Actively managed · Listing
Most notable sale · Guardant Health, Inc.
Guardant Health, Inc. cut by 40%
Shares went from 8,286 to 4,952 ($1.07M → $787K). Now 4.0% of the portfolio. Estimated trade $530K.
Most notable buy · UnitedHealth Group Incorporated
UnitedHealth Group Incorporated raised 4.1x
Shares went from 715 to 2,912 ($272K → $1.13M). Now 5.8% of the portfolio. Estimated trade $856K.
Largest holding: Eli Lilly and Company, cut 15%, 2,066 shares ($2.39M).
| Current positions Top 10 | % of book |
|---|---|
| Eli Lilly and Company LLY $2.39M · −15% sh | 12.1% |
| Johnson & Johnson JNJ $1.63M · −15% sh | 8.3% |
| Merck & Company, Inc. MRK $1.46M · −2% sh | 7.4% |
| UnitedHealth Group Incorporated UNH $1.13M · 4.1x sh | 5.8% |
| Vertex Pharmaceuticals Incorporated VRTX $823K · 2.3x sh | 4.2% |
| argenx SE ARGX $812K · −20% sh | 4.1% |
| Guardant Health, Inc. GH $787K · −40% sh | 4.0% |
| DexCom, Inc. DXCM $757K · +9% sh | 3.8% |
| Agilent Technologies, Inc. A $689K · +9% sh | 3.5% |
| Thermo Fisher Scientific Inc TMO $687K · −40% sh | 3.5% |
Slices are % of holdings value. Changes ("sh" shares, "units" other holdings) are in the quantity held against May 31, 2026.
| Sectors | % of holdings value |
|---|---|
| Healthcare | 93.1% |
| Financial Services | 1.7% |
| Technology | 1.7% |
| Unclassified | 3.5% |
| Industries | % of holdings value |
|---|---|
| Drug Manufacturers - General | 29.8% |
| Biotechnology | 23.8% |
| Medical Devices | 13.8% |
| Medical Instruments & Supplies | 7.5% |
| Diagnostics & Research | 6.9% |
| Healthcare Plans | 5.8% |
| Drug Manufacturers - Specialty & Generic | 2.8% |
| Other (3) | 6.1% |
| Unclassified | 3.5% |
| Initiations 3 | Value |
|---|---|
| Natera, Inc. NTRA 1.6% of portfolio | $307K |
| Dianthus Therapeutics, Inc. DNTH 0.9% of portfolio | $186K |
| Kardigan, Inc. KARD 0.5% of portfolio | $96.3K |
| Increases 12 | Change |
|---|---|
| UnitedHealth Group Incorporated UNH $272K → $1.13M | 4.1x |
| Vertex Pharmaceuticals Incorporated VRTX $299K → $823K | 2.3x |
| Quest Diagnostics Incorporated DGX $144K → $270K | +52% |
| Spyre Therapeutics, Inc. SYRE $70.6K → $151K | +76% |
| DexCom, Inc. DXCM $562K → $757K | +9% |
| GALDERMA GROUP AG GALD $220K → $274K | +27% |
| Agilent Technologies, Inc. A $556K → $689K | +9% |
| Edwards Lifesciences Corporation EW $600K → $681K | +8% |
| Cytokinetics, Incorporated CYTK $281K → $309K | +19% |
| Structure Therapeutics Inc. GPCR $39.7K → $84.4K | +82% |
| Praxis Precision Medicines, Inc. PRAX $111K → $142K | +28% |
| BridgeBio Pharma, Inc. BBIO $147K → $185K | +9% |
| Reductions 24 | Change |
|---|---|
| Guardant Health, Inc. GH $1.07M → $787K | −40% |
| Boston Scientific Corporation BSX $760K → $302K | −60% |
| AstraZeneca AZN $974K → $396K | −53% |
| Thermo Fisher Scientific Inc TMO $910K → $687K | −40% |
| Eli Lilly and Company LLY $2.67M → $2.39M | −15% |
| Johnson & Johnson JNJ $1.62M → $1.63M | −15% |
| Hoya Corporation 7741 $710K → $400K | −38% |
| argenx SE ARGX $818K → $812K | −20% |
| Intuitive Surgical, Inc. ISRG $785K → $575K | −17% |
| Xenon Pharmaceuticals Inc. XENE $272K → $179K | −40% |
| CG Oncology, Inc. CGON $151K → $72.2K | −61% |
| Lonza Group Ltd O6Z $563K → $550K | −12% |
| Terminations 5 | Change |
|---|---|
| Apogee Therapeutics, Inc. APGE was $396K | −100% |
| Penumbra, Inc. PEN was $323K | −100% |
| Ionis Pharmaceuticals, Inc. IONS was $276K | −100% |
| Revolution Medicines, Inc. RVMD was $168K | −100% |
| Insulet Corporation PODD was $57.7K | −100% |
The other 12 reductions
Roivant Sciences Ltd. (−12%), Royalty Pharma plc (−12%), Mettler-Toledo International, Inc. (−12%), Repligen Corporation (−12%), Cencora, Inc. (−7%), Insmed Incorporated (−12%), Merck & Company, Inc. (−2%), Madrigal Pharmaceuticals, Inc. (−13%), Definium Therapeutics, Inc. (−12%), Rhythm Pharmaceuticals, Inc. (−12%), Alkermes plc (−12%), Sartorius Stedim Biotech S.A. (−12%)
Source: the fund's quarterly portfolio reports to the SEC, the portfolio of Aug 31, 2026 (Form N-PORT) vs the portfolio of May 31, 2026 (Form N-PORT). Percent changes are changes in the quantity held (shares, or units for holdings that are not a listed equity); dollar values are as reported at each period end. Each column is ranked by the estimated dollar size of the trade: a new or closed position at its value, otherwise the change in shares at the position's own period-end price. Where shares and price per share moved by inverse whole multiples (a split), the earlier share count is restated. Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.
Objective
From the summary prospectus filed Dec 29, 2025.
The Goldman Sachs Future Health Care Equity ETF (the "Fund") seeks long-term growth of capital.
Principal investment strategies
The Fund invests, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes (measured at the time of purchase) ("Net Assets") in equity investments in U.S. and non-U.S. health care companies. Goldman Sachs Asset Management, L.P. ("GSAM" or the "Investment Adviser") generally defines a health care company as a company in the health care sector. The Investment Adviser may use the classifications assigned by third parties but is not required to do so. The Fund seeks to achieve its investment objective by investing in health care companies that the Investment Adviser believes are driving innovation in health care, by developing either new treatments or new technologies, primarily in the fields of genomics, precision medicine, technology-enabled procedures and digital healthcare. The Investment Adviser seeks to identify companies at various growth stages, including dominant businesses with strong competitive advantages, companies that are early innovators and have developed new treatments or technologies, and companies that are enabling new treatments or technologies that have the potential to disrupt existing markets or serve existing markets more efficiently. Equity investments may include common stock, preferred stock, warrants and other rights to acquire stock, American depositary receipts ("ADRs"), European depositary receipts ("EDRs"), and global depositary receipts ("GDRs"), underlying funds (including exchange-traded funds ("ETFs")), and futures, forwards, options and other instruments with similar economic exposures. The Fund may invest in companies that only recently began to trade publicly. The Fund may invest in underlying ETFs, exchange-traded products ("ETPs") and/or money market funds, including those that currently exist or that may become available for investment in the future for which the Investment Adviser or an affiliate now or in the future acts as investment adviser or principal underwriter. The Fund may also invest in unaffiliated ETFs, ETPs and/or money market funds. 2 Summary Prospectus — Goldman Sachs Future Health Care Equity ETF The Fund generally intends to invest in companies that the Investment Adviser believes are aligned with key themes associated with innovation in health care, which include, but are not limited to, genomics, precision medicine, technology-enabled procedures, and digital healthcare (the "Key Themes"). The Key Themes currently are: Genomics: represents companies that, in the Investment Adviser's view, provide, invest in or help create products, services or technologies in areas including, but not limited to, sequencing, diagnostic testing and the genomics supply chain. Precision Medicine: represents companies that, in the Investment Adviser's view, provide, invest in or help create products, services or technologies in areas including, but not limited to, targeted oncology, gene/cell therapy and rare diseases. Technology-Enabled Procedures: represents companies that, in the Investment Adviser's view, provide, invest in or help create products, services or technologies in areas including, but not limited to, robotic surgery and minimally invasive procedures. Digital Healthcare: represents companies that, in the Investment Adviser's view, provide, invest in or help create products, services or technologies in areas including, but not limited to, connected devices, digital transformation, and online health. The Key Themes and related areas of investment may change over time at the sole discretion of the Investment Adviser without prior notice to shareholders. In addition, the Fund is permitted to make investments that are not aligned with the Key Themes. In selecting investments, the Investment Adviser will not seek to allocate a specified portion of the Fund's portfolio to each particular Key Theme, and the allocation of the Fund's investments across the Key Themes will vary over time in the Investment Adviser's sole discretion.
Management and Contact
- Adviser
- Goldman Sachs Asset Management, L.P.
- Portfolio managers
-
Jenny Chang, Managing Director; and Raj Garigipati, Managing Director, have each managed the Fund since November 2021. 5 Summary Prospectus — Goldman Sachs Future Health Care Equity ETF
- Phone
- 800-621-2550
- [email protected]
Holdings as of Aug 31, 2026
The full portfolio as of the quarter end Aug 31, 2026, from the fund's report to the SEC (Form N-PORT, filed Oct 27, 2026), the newest we have: we do not read a daily file from this fund's website, or the filing is newer. Every line is listed: holdings we could identify link to their page, the rest (bonds, CLOs, loans, derivatives, securities we do not carry) are shown as filed, debt with its coupon and maturity; Shares is the principal amount for debt. Short positions are negative. Change is the share count against the filing of May 31, 2026.
41 lines, 38 linked, weights sum to 100.41% · Actively managed (N-CEN)
| Holding | Ticker / identifier | Type | Shares | Change | Weight | Market value |
|---|---|---|---|---|---|---|
| ELI LILLY & COMPANY | LLY US5324571083 | Equity | 2,066 | −351 | 12.19% | $ 2.39M |
| JOHNSON & JOHNSON | JNJ US4781601046 | Equity | 6,127 | −1,077 | 8.31% | $ 1.629M |
| MERCK & COMPANY INC | MRK US58933Y1055 | Equity | 9,861 | −212 | 7.44% | $ 1.457M |
| UNITEDHEALTH GROUP INC | UNH US91324P1021 | Equity | 2,912 | +2,197 | 5.79% | $ 1.134M |
| VERTEX PHARMACEUTICALS INC | VRTX US92532F1003 | Equity | 1,511 | +844 | 4.20% | $ 822.77K |
| ARGENX SE | ARGX US04016X1019 | Equity | 787 | −192 | 4.14% | $ 811.916K |
| GUARDANT HEALTH INC | GH US40131M1099 | Equity | 4,952 | −3,334 | 4.02% | $ 787.467K |
| DEXCOM INC | DXCM US2521311074 | Equity | 8,317 | +696 | 3.86% | $ 757.346K |
| AGILENT TECHNOLOGIES INC | A US00846U1016 | Equity | 4,485 | +380 | 3.51% | $ 688.717K |
| THERMO FISHER SCIENTIFIC INC | TMO US8835561023 | Equity | 1,114 | −733 | 3.51% | $ 687.449K |
| EDWARDS LIFESCIENCES CORP | EW US28176E1082 | Equity | 7,509 | +570 | 3.48% | $ 681.442K |
| INTUITIVE SURGICAL INC | ISRG US46120E6023 | Equity | 1,526 | −323 | 2.93% | $ 575.088K |
| LONZA GROUP AG | LONN CH0013841017 | Equity | 771 | −108 | 2.81% | $ 550.23K |
| CENCORA INC | COR US03073E1055 | Equity | 1,619 | −131 | 2.67% | $ 523.908K |
| ROIVANT SCIENCES LTD | ROIV BMG762791017 | Equity | 14,044 | −1,992 | 2.48% | $ 486.484K |
| HOYA CORP | 7741 JP3837800006 | Equity | 2,595 | −1,578 | 2.04% | $ 399.743K |
| ASTRAZENECA PLC | AZN GB0009895292 | Equity | 2,440 | −2,794 | 2.02% | $ 395.986K |
| ROYALTY PHARMA PLC | RPRX GB00BMVP7Y09 | Equity | 5,584 | −786 | 1.75% | $ 342.913K |
| METTLER-TOLEDO INTERNATIONAL INC | MTD US5926881054 | Equity | 238 | −33 | 1.71% | $ 334.423K |
| REPLIGEN CORP | RGEN US7599161095 | Equity | 1,789 | −249 | 1.65% | $ 323.773K |
|
Goldman Sachs Trust
|
FTOXX US38141W3236 | Money market | 311,849.22 | +23,860.64 | 1.59% | $ 311.849K |
| CYTOKINETICS INC | CYTK US23282W6057 | Equity | 4,355 | +692 | 1.58% | $ 308.813K |
| NATERA INC | NTRA US6323071042 | Equity | 955 | new +955 | 1.57% | $ 307.472K |
| BOSTON SCIENTIFIC CORP | BSX US1011371077 | Equity | 6,257 | −9,483 | 1.54% | $ 302.213K |
|
GALDERMA GROUP AG
|
GALD CH1335392721 | Equity | 1,318 | +284 | 1.40% | $ 273.893K |
| QUEST DIAGNOSTICS INC | DGX US74834L1008 | Equity | 1,125 | +384 | 1.38% | $ 270.338K |
| INSMED INC | INSM US4576693075 | Equity | 1,823 | −258 | 1.13% | $ 222.078K |
| MADRIGAL PHARMACEUTICALS INC | MDGL US5588681057 | Equity | 376 | −54 | 1.04% | $ 203.051K |
| DIANTHUS THERAPEUTICS INC | DNTH US2528281080 | Equity | 1,761 | new +1,761 | 0.95% | $ 185.979K |
| BRIDGEBIO PHARMA INC | BBIO US10806X1028 | Equity | 2,421 | +207 | 0.95% | $ 185.424K |
| XENON PHARMACEUTICALS INC | XENE CA98420N1050 | Equity | 2,974 | −2,003 | 0.91% | $ 179.094K |
| SPYRE THERAPEUTICS INC | SYRE US00773J2024 | Equity | 1,690 | +730 | 0.77% | $ 150.968K |
| DEFINIUM THERAPEUTICS INC | DFTX CA24477V1058 | Equity | 3,695 | −519 | 0.75% | $ 146.765K |
| RHYTHM PHARMACEUTICALS INC | RYTM US76243J1051 | Equity | 1,346 | −192 | 0.73% | $ 142.851K |
| PRAXIS PRECISION MEDICINES INC | PRAX US74006W2070 | Equity | 406 | +90 | 0.73% | $ 142.222K |
| ALKERMES PLC | ALKS IE00B56GVS15 | Equity | 2,367 | −336 | 0.57% | $ 111.225K |
| SARTORIUS STEDIM BIOTECH SA | DIM FR0013154002 | Equity | 467 | −66 | 0.54% | $ 106.324K |
| KARDIGAN INC | KARD US4859251013 | Equity | 4,775 | new +4,775 | 0.49% | $ 96.264K |
|
GOLDMAN SACHS FINANCIAL SQUARE FUNDS PRIME OBLIGATIONS FUND
|
FGTXX | Money market | 94,704.09 | new +94,704.09 | 0.48% | $ 94.704K |
| STRUCTURE THERAPEUTICS INC | GPCR US86366E1064 | Equity | 1,838 | +830 | 0.43% | $ 84.383K |
| CG ONCOLOGY INC | CGON US1569441009 | Equity | 960 | −1,472 | 0.37% | $ 72.154K |
Trades May 31, 2026 to Aug 31, 2026
Changes in shares between the fund's two newest published portfolios, cash left out. Value is the change at the line's own price in the newer portfolio.
| Holding | Ticker | Action | Before | After | Change | Value |
|---|---|---|---|---|---|---|
| UNITEDHEALTH GROUP INC | UNH | Bought | 715 | 2,912 | +2,197 | $ 855.534K |
| GUARDANT HEALTH INC | GH | Sold | 8,286 | 4,952 | −3,334 | $ -530.173K |
| VERTEX PHARMACEUTICALS INC | VRTX | Bought | 667 | 1,511 | +844 | $ 459.575K |
| BOSTON SCIENTIFIC CORP | BSX | Sold | 15,740 | 6,257 | −9,483 | $ -458.029K |
| ASTRAZENECA PLC | AZN | Sold | 5,234 | 2,440 | −2,794 | $ -453.436K |
| THERMO FISHER SCIENTIFIC INC | TMO | Sold | 1,847 | 1,114 | −733 | $ -452.334K |
| ELI LILLY & COMPANY | LLY | Sold | 2,417 | 2,066 | −351 | $ -406.012K |
| APOGEE THERAPEUTICS INC | APGE | Closed | 4,823 | — | −4,823 | $ -396.161K |
| PENUMBRA INC | PEN | Closed | 1,015 | — | −1,015 | $ -323.075K |
| NATERA INC | NTRA | New | — | 955 | +955 | $ 307.472K |
| JOHNSON & JOHNSON | JNJ | Sold | 7,204 | 6,127 | −1,077 | $ -286.32K |
| IONIS PHARMACEUTICALS INC | IONS | Closed | 3,614 | — | −3,614 | $ -276.471K |
| HOYA CORP | 7741 | Sold | 4,173 | 2,595 | −1,578 | $ -243.081K |
| ARGENX SE | ARGX | Sold | 979 | 787 | −192 | $ -198.079K |
| DIANTHUS THERAPEUTICS INC | DNTH | New | — | 1,761 | +1,761 | $ 185.979K |
| REVOLUTION MEDICINES INC | RVMD | Closed | 1,069 | — | −1,069 | $ -168.346K |
| INTUITIVE SURGICAL INC | ISRG | Sold | 1,849 | 1,526 | −323 | $ -121.726K |
| XENON PHARMACEUTICALS INC | XENE | Sold | 4,977 | 2,974 | −2,003 | $ -120.621K |
| CG ONCOLOGY INC | CGON | Sold | 2,432 | 960 | −1,472 | $ -110.636K |
| KARDIGAN INC | KARD | New | — | 4,775 | +4,775 | $ 96.264K |
| QUEST DIAGNOSTICS INC | DGX | Bought | 741 | 1,125 | +384 | $ 92.275K |
| LONZA GROUP AG | LONN | Sold | 879 | 771 | −108 | $ -77.075K |
| ROIVANT SCIENCES LTD | ROIV | Sold | 16,036 | 14,044 | −1,992 | $ -69.003K |
| SPYRE THERAPEUTICS INC | SYRE | Bought | 960 | 1,690 | +730 | $ 65.211K |
| DEXCOM INC | DXCM | Bought | 7,621 | 8,317 | +696 | $ 63.378K |
|
GALDERMA GROUP AG
|
GALD | Bought | 1,034 | 1,318 | +284 | $ 59.018K |
| AGILENT TECHNOLOGIES INC | A | Bought | 4,105 | 4,485 | +380 | $ 58.353K |
| INSULET CORP | PODD | Closed | 398 | — | −398 | $ -57.686K |
| EDWARDS LIFESCIENCES CORP | EW | Bought | 6,939 | 7,509 | +570 | $ 51.728K |
| CYTOKINETICS INC | CYTK | Bought | 3,663 | 4,355 | +692 | $ 49.07K |
| ROYALTY PHARMA PLC | RPRX | Sold | 6,370 | 5,584 | −786 | $ -48.268K |
| METTLER-TOLEDO INTERNATIONAL INC | MTD | Sold | 271 | 238 | −33 | $ -46.37K |
| REPLIGEN CORP | RGEN | Sold | 2,038 | 1,789 | −249 | $ -45.064K |
| CENCORA INC | COR | Sold | 1,750 | 1,619 | −131 | $ -42.392K |
| STRUCTURE THERAPEUTICS INC | GPCR | Bought | 1,008 | 1,838 | +830 | $ 38.105K |
| PRAXIS PRECISION MEDICINES INC | PRAX | Bought | 316 | 406 | +90 | $ 31.527K |
| INSMED INC | INSM | Sold | 2,081 | 1,823 | −258 | $ -31.43K |
| MERCK & COMPANY INC | MRK | Sold | 10,073 | 9,861 | −212 | $ -31.325K |
| MADRIGAL PHARMACEUTICALS INC | MDGL | Sold | 430 | 376 | −54 | $ -29.162K |
| DEFINIUM THERAPEUTICS INC | DFTX | Sold | 4,214 | 3,695 | −519 | $ -20.615K |
| RHYTHM PHARMACEUTICALS INC | RYTM | Sold | 1,538 | 1,346 | −192 | $ -20.377K |
| BRIDGEBIO PHARMA INC | BBIO | Bought | 2,214 | 2,421 | +207 | $ 15.854K |
| ALKERMES PLC | ALKS | Sold | 2,703 | 2,367 | −336 | $ -15.789K |
| SARTORIUS STEDIM BIOTECH SA | DIM | Sold | 533 | 467 | −66 | $ -15.026K |
Podcast Mentions
Sign up to see podcast mentions and sentiment
Sign Up